Wall Street analysts predict that Eagle Pharmaceuticals Inc (NASDAQ:EGRX) will announce earnings of $0.75 per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Eagle Pharmaceuticals’ earnings, with estimates ranging from $0.55 to $0.94. Eagle Pharmaceuticals posted earnings per share of $0.53 during the same quarter last year, which would indicate a positive year-over-year growth rate of 41.5%. The company is scheduled to issue its next earnings results on Thursday, May 9th.

On average, analysts expect that Eagle Pharmaceuticals will report full year earnings of $3.68 per share for the current year, with EPS estimates ranging from $3.24 to $4.12. For the next fiscal year, analysts expect that the company will report earnings of $3.76 per share, with EPS estimates ranging from $3.55 to $3.97. Zacks’ EPS calculations are an average based on a survey of sell-side research analysts that cover Eagle Pharmaceuticals.

Eagle Pharmaceuticals (NASDAQ:EGRX) last issued its quarterly earnings data on Thursday, February 28th. The specialty pharmaceutical company reported $1.20 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.16 by $0.04. Eagle Pharmaceuticals had a return on equity of 17.76% and a net margin of 14.96%. The firm had revenue of $56.05 million during the quarter, compared to the consensus estimate of $54.17 million. During the same quarter in the previous year, the company posted $1.05 EPS. The business’s revenue for the quarter was up 19.8% compared to the same quarter last year.

A number of equities research analysts recently commented on EGRX shares. ValuEngine raised Eagle Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, March 1st. Royal Bank of Canada set a $66.00 price target on Eagle Pharmaceuticals and gave the company a “buy” rating in a report on Friday, March 1st. BidaskClub upgraded Eagle Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, February 23rd. Cantor Fitzgerald reiterated a “hold” rating and set a $58.00 target price on shares of Eagle Pharmaceuticals in a report on Thursday, February 28th. Finally, Zacks Investment Research raised Eagle Pharmaceuticals from a “hold” rating to a “buy” rating and set a $49.00 price target on the stock in a research report on Friday, January 18th. Two research analysts have rated the stock with a sell rating, four have given a hold rating and two have given a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $63.67.

Shares of NASDAQ EGRX traded up $0.28 during midday trading on Monday, hitting $48.09. The stock had a trading volume of 7,522 shares, compared to its average volume of 171,793. The company has a debt-to-equity ratio of 0.24, a quick ratio of 3.92 and a current ratio of 4.13. Eagle Pharmaceuticals has a fifty-two week low of $36.03 and a fifty-two week high of $85.66. The stock has a market capitalization of $677.49 million, a P/E ratio of 23.08 and a beta of 1.72.

In other news, CEO Scott Tarriff sold 30,085 shares of the stock in a transaction on Friday, February 1st. The stock was sold at an average price of $41.54, for a total value of $1,249,730.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold a total of 79,488 shares of company stock valued at $3,752,208 over the last quarter. 28.20% of the stock is owned by corporate insiders.

Several institutional investors and hedge funds have recently made changes to their positions in EGRX. LS Investment Advisors LLC lifted its stake in shares of Eagle Pharmaceuticals by 97.9% in the 4th quarter. LS Investment Advisors LLC now owns 2,157 shares of the specialty pharmaceutical company’s stock valued at $87,000 after acquiring an additional 1,067 shares during the last quarter. Flinton Capital Management LLC lifted its stake in shares of Eagle Pharmaceuticals by 23.9% in the 4th quarter. Flinton Capital Management LLC now owns 2,464 shares of the specialty pharmaceutical company’s stock valued at $99,000 after acquiring an additional 476 shares during the last quarter. Acadian Asset Management LLC increased its holdings in Eagle Pharmaceuticals by 82.1% in the fourth quarter. Acadian Asset Management LLC now owns 3,008 shares of the specialty pharmaceutical company’s stock valued at $121,000 after purchasing an additional 1,356 shares during the period. Neuburgh Advisers LLC increased its holdings in Eagle Pharmaceuticals by 23.9% in the fourth quarter. Neuburgh Advisers LLC now owns 2,992 shares of the specialty pharmaceutical company’s stock valued at $121,000 after purchasing an additional 578 shares during the period. Finally, Municipal Employees Retirement System of Michigan acquired a new stake in Eagle Pharmaceuticals in the fourth quarter valued at $128,000. Institutional investors own 94.36% of the company’s stock.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers Argatroban, an anti-coagulant thrombin inhibitor for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma (NHL); and Belrapzo, a chemotherapeutic agent for CLL and Indolent NHL.

Recommended Story: How does new data get added to a blockchain?

Get a free copy of the Zacks research report on Eagle Pharmaceuticals (EGRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.